

INDEX TO VOLUME 27  
AUTHOR INDEX

- Adams, R.J., 347, 363  
Almonte, H., 311  
Alsbach, G.P.J., 409  
Alvarez, F., 123  
Arreola, M., 311  
Asch, R.H., 619  
Balamceda, J.P., 619  
Balogh, S.A., 63  
Bardin, C.W., 627  
Barkfeldt, J.O.A., 423  
Bartlett, K.H., 497  
Basnayake, S., 453, 465  
Beck, L.R., 201  
Bejar, E., 227, 239, 255, 267  
Benson, H.D., 95  
Berry, S.J., 347  
Booth, M., 39  
Bordy, M.J., 347  
Borghi, M.R., 619  
Bounds, W., 39  
Brache, V., 123  
Braun, J., 483  
Breneman, W.R., 639  
Burrow, G.N., 627  
Bygdeman, M., 51, 141  
Canfield, R.E., 627  
Carlborg, L., 439  
Casado, M.E., 1, 13, 27  
Chatterji, D., 195  
Chen, Q.Q., 391  
Chow, A.W., 497  
Christenssen, N.J., 51, 141  
Cochran, R.C., 347, 363  
Comite, F., 195  
Córdova, M.S., 289  
Coy, D.H., 619  
Croxatto, H.B., 1, 13, 27, 281  
Cutler, G.P., Jr., 195  
Darney, K.J., Jr., 347  
Decker, M.H., 195  
Demey-Ponsart, E., 577  
Desjardins, C., 347, 363, 383  
Díaz, S., 1, 13, 27, 281  
Diczfalusy, E., 177  
Dinh, J., 483  
Durán, E., 1, 13, 27  
Duvivier, J., 577  
Ehrlich, P.H., 627  
Eneroth, P., 329  
Enríquez, R.G., 227, 239, 255, 267  
Estrada, A.V., 227, 239, 255, 267  
Etchegoyen, G., 591  
Ewing, L.L., 347, 363, 383  
Fajumi, J.O., 161  
Faundes, A., 123  
Fleetwood, L., 329  
Forbes, A.D., 383  
Fotherby, K., 153  
Franchimont, P., 577  
Franck, E.R., 409  
Fraser, I., 531  
Fu, W.O., 391  
Gallegos, A.J., 211, 227, 239, 255, 267  
Gallelli, J.F., 195  
Galván, E., 591  
Garza-Flores, J., 289

## CONTRACEPTION

- Gaspard, U.J., 577  
 Gillain, D., 577  
 Girón, H., 227, 239, 255, 267  
 Goh, T.H., 75  
 Goldstein, M., 627  
 Gréen, 51, 141  
 Grunwell, J.F., 95  
 Guillebaud, 39  
 Hagenfeldt, K., 69  
 Hanafiah, M.J., 75  
 Haukkamaa, M., 571  
 Heine, M.W., 401  
 Herreros, C., 1, 13, 27  
 Ho, P.C., 339  
 Hong, S.S., 299, 605  
 Huber, A.C., 363  
 Hulting, A.-L., 69  
 Hutapea, H., 75  
 Jansen, R.P.S., 531  
 Jaszczak, S.E., 505  
 Johannisson, E., 177  
 Johansson, E.D.B., 123  
 Johnston, J.O., 95  
 Juez, G. 1, 13, 27  
 Karim, S.M.M., 75  
 Kato, K., 515  
 Kemp, P.L., 383  
 Kiriwat, O., 153  
 Kirton, K.T., 383  
 Kosonen, A., 85  
 Kurunmäki, H., 473  
 Kwak, H.M., 299  
 Lähteenmäki, P., 553  
 Lähteenmäki, P.L.A., 553  
 Landeros, J., 591  
 Landgren, B.-M., 177, 329  
 Lau, I., 521  
 Lee, W.M., 391  
 Liang, S.T., 339  
 Lim, L.S., 75  
 Lince, E., 289  
 Lobl, T.J., 383  
 Lopez, F., 311  
 Loriaux, D.L., 195  
 Lox, C.D., 401  
 Lozoya, X., 227, 239, 255, 267  
 Luukkainen, T., 571  
 Ma, H.K., 339  
 Macaulay, L.K., 131  
 McCarthy, T., 75  
 Mertzluft, J., 521  
 Miller, P.C., 453, 465  
 Miranda, P., 1, 13, 27  
 Monarrez, G., 311  
 Nash, H.A., 123, 483  
 Navarro, C., 311  
 Niesvisky, R., 619  
 O'Brien, F.B., 111  
 Odland, V., 123, 423  
 Ortiz, E., 311  
 Pavez, M., 281  
 Pedrón, N., 255  
 Peralta, O., 1, 13, 27  
 Percival-Smith, R., 497  
 Perez-Palacios, G., 591  
 Pérez-Toral, M.C., 289  
 Perkin, G.W., 311  
 Petrow, V., 95  
 Piedras, J., 289  
 Pittaway, D.E., 431  
 Ponce-Monter, H., 227, 239, 255, 267  
 Poortman, J., 409

## CONTRACEPTION

- Pope, C.E., 201  
 Pope, V.Z., 201  
 Ratnam, S.S., 75  
 Ratsula, K., 571  
 Rivera, R., 311  
 Robertson, D.N., 281, 483  
 Roche, P.C., 131  
 Rogers, S., 453, 465  
 Romus, M.A., 577  
 Roseman, T.J., 141  
 Rowlands, S., 39  
 Ruiz, R., 311  
 Ryu, K., 299, 605  
 Sairam, M.R., 515  
 Saksena, S., 521  
 Salvatierra, A.M., 1, 13, 27  
 Schally, A.V., 619  
 Sen, D.K., 75  
 Shaw, S.T., 131  
 Shumin, X., 177  
 Shu-rong, Z., 329  
 Simandjuntak, P., 75  
 Sinnathuray, 75  
 Sivanesaratnam, 75  
 Sivin, I., 483  
 Southam, L., 255  
 Spilman, C.H., 141  
 Stewart, W.C., 111  
 Strandberg, J.D., 363  
 Sturtevant, F.M. 111  
 Sun, N.C., 131  
 Tanaka, M.S., Jr., 131  
 Tang, G.W.K., 339  
 Thau, R.B., 627  
 Thiery, M., 85  
 Thijssen, J.H.H., 409  
 Toivonen, J., 553  
 Tsang, A.Y.F., 391  
 Tuttle, M.E., 141  
 Vesterqvist, O., 141  
 Victor, A., 423  
 Victor de Silva, S., 453, 465  
 Werner, S., 69  
 West, C.P., 553  
 White, M.J., 521  
 Wichmann, K., 571  
 Winterer, J., 195  
 Witkin, S.S., 627  
 Wolpert, E., 591  
 Wong, P.Y.D., 391  
 Yamamoto, Y., 627  
 Yu, H.K., 299  
 Zeller, F.J., 639

the 1990s, the number of people in the world who are undernourished has increased from 600 million to 800 million (FAO 1996). The number of people who are malnourished has increased from 1.1 billion to 1.5 billion (FAO 1996).

There are a number of reasons why the number of people who are undernourished has increased. One of the main reasons is that the world population has increased. The world population is now over 6 billion and is expected to reach 9 billion by the year 2050 (FAO 1996).

Another reason why the number of people who are undernourished has increased is that the world's food supply is not increasing fast enough to keep up with the growing population. The world's food supply is expected to be 40% short by the year 2050 (FAO 1996).

A third reason why the number of people who are undernourished has increased is that the world's food supply is not distributed evenly. In some parts of the world, there is a surplus of food, while in other parts, there is a shortage (FAO 1996).

There are a number of ways in which the world's food supply can be increased. One way is to increase the amount of land that is used for agriculture. Another way is to increase the amount of food that is produced on the same amount of land (FAO 1996).

There are a number of ways in which the world's food supply can be distributed more evenly. One way is to reduce the amount of food that is wasted. Another way is to increase the amount of food that is distributed to the people who need it most (FAO 1996).

There are a number of ways in which the world's food supply can be made more sustainable. One way is to use less land for agriculture. Another way is to use less water for agriculture (FAO 1996).

There are a number of ways in which the world's food supply can be made more secure. One way is to increase the amount of food that is stored. Another way is to increase the amount of food that is distributed to the people who need it most (FAO 1996).

There are a number of ways in which the world's food supply can be made more affordable. One way is to reduce the cost of food. Another way is to increase the amount of food that is distributed to the people who need it most (FAO 1996).

There are a number of ways in which the world's food supply can be made more accessible. One way is to increase the amount of food that is distributed to the people who need it most. Another way is to increase the amount of food that is distributed to the people who need it most (FAO 1996).

There are a number of ways in which the world's food supply can be made more available. One way is to increase the amount of food that is distributed to the people who need it most. Another way is to increase the amount of food that is distributed to the people who need it most (FAO 1996).

There are a number of ways in which the world's food supply can be made more abundant. One way is to increase the amount of food that is distributed to the people who need it most. Another way is to increase the amount of food that is distributed to the people who need it most (FAO 1996).

## INDEX TO VOLUME 27

### SUBJECT INDEX

- A-LH-RH ([N-Ac-D-Trp<sup>1,3</sup>,D-p-Cl-Phe<sup>2</sup>,D-Phe<sup>6</sup>,D-Ala<sup>10</sup>]-LH-RH)
- Abortifacient effect, synthetic androstane derivatives (baboon), 201
- Acceptability,
- comparison of ethinyl oestradiol + levonorgestrel monophasic and triphasic versions, 439
  - norethisterone during breast-feeding, 563
- Accidental pregnancy, randomised comparative evaluation of Cu-IUDs, 75
- 1 $\beta$ -Acetoxy-17 $\alpha$ -ethinyl-17-hydroxy-18-methyl-4-ostren-3-on, abortifacient effect (baboon), 201
- 1 $\beta$ -17 $\beta$ -Acetoxy-18-methyl-4-ostren-3-on, abortifacient effect (baboon), 201
- Age, effect on incidence of pelvic inflammatory disease during Cu-7 clinical trials, III
- Agonistic analogue of LH-RH, D-Trp<sup>6</sup>-LH-RH, 619
- Aldosterone level,
- effect of ethinylestradiol + desogestrel monophasic, 577
  - effect of ethinylestradiol + desogestrel sequential, 577
  - effect of ethinylestradiol + levonorgestrel triphasic, 577
- Androgenic/antiandrogenic activity, effect of RMI 12,936 (rat), 95
- Androstane derivatives, abortifacient effect (baboon), 201
- 5-Androstene-3, 17-dione, effect on 17 $\beta$ -hydroxysteroid oxidoreductase activity (dog), 431
- Anemia development after T Cu 220 insertion, predictive value of serum ferritin, 289
- Anemic women,
- effects of ethinylestradiol + levonorgestrel on levels of hemoglobin, serum iron and iron binding capacity, 311
  - effects of ethinylestradiol + levonorgestrel with ferrous fumarate on levels of hemoglobin, serum iron and iron binding capacity, 311
  - effects of IUDs on levels of hemoglobin, serum iron and iron binding capacity, 311
- Anovulatory luteal cycles (monkey), 505
- Antagonistic activity, deglycosylated hCG (rat), 515
- Antagonistic analogue of LH-RH, [N-Ac-D-Trp<sup>1,3</sup>,D-p-Cl-Phe<sup>2</sup>,D-Phe<sup>6</sup>,D-Ala<sup>10</sup>]-LH-RH, 619
- Anti-hCG antiserum,
- antibody titers using the recommended standard assay, 627
  - binding of hormones and subunits, 627

## CONTRACEPTION

- characterization, 627
- determination of isoantibody class, 627
- Antifertility assay, RMI 12,936 (hamster), 95
- Antigonadotropic activity, effect of RMI 12,936 (rat), 95
- Antinogestational steroid, RMI 12,936, 95
- Antiuterotrophic/antiestrogenic activity, effect of RMI 12,936 (rat), 95
- Asialo hCG, effect on action of hCG (rat), 515
- bCH (baboon chorionic gonadotropin)
- bCH level, effect of synthetic androstane derivative (baboon), 201
- Bile lithogenic index,
  - effect of ethinyl estradiol + l-norgestrel, 591
  - effect of norethisterone enanthate, 591
- Biliary lipid composition,
  - effect of ethinyl estradiol + l-norgestrel, 591
  - effect of norethisterone enanthate, 591
- Biological activity of D-trp<sup>6</sup>-pro<sup>9</sup>-NET-LHRH, assessment for stability of solutions, 195
- Biological observations, zoapatle, 211
- Biological properties, zoapatle aqueous crude extract (guinea pig), 239
- Bleeding duration, comparison of ethinyl oestradiol + levonorgestrel monophasic and triphasic versions, 439
- Bleeding patterns, effect of norethisterone during breast-feeding, 563
- Blood chemistry,
  - effect of testosterone + estradiol implant (monkey), 363, 383
  - effect of zoapatle aqueous crude extract (rat), 255
- Blood clotting, effect of testosterone + estradiol implant (monkey), 363
- Blood loss at vacuum aspiration,
  - comparison of different prostaglandin analogues and laminaria for preoperative cervical dilatation in late first trimester abortion, 51
  - pre-operative 16,16-dimethyl-trans- $\Delta^2$ PGE<sub>1</sub> methyl ester, 339
- Blood pressure,
  - comparison of mestranol + norethindrone and ethinyl estradiol + norethindrone, 453
  - effect of levonorgestrel-releasing capsules, 473
  - effect of Nova-T, 473
- Blood production rate of estradiol, effect of testosterone + estradiol implant (monkey) 347
- Blood production rate of testosterone, effect of testosterone + estradiol implant (monkey), 347

## Body weight,

- comparison of mestranol + norethindrone and ethinyl estradiol + norethindrone, 453
- effect of levonorgestrel-releasing capsules, 473
- effect of lithosperm (chick), 639
- effect of lithosperm and propylthiouracil (chick), 639
- effect of Nova-T, 473
- effect of zoapatle aqueous crude extract (rat, dog), 255

## Botanical and ecological determinants, zoapatle, 227

## Breast-feeding,

- acceptability of norethisterone, 563
- effect of oral contraceptive regimens, 531

## Breast-feeding duration, effect of norethisterone, 563

## Cadmium-induced sterility, effect of zinc (rat), 521

## Capsules containing levonorgestrel,

- levonorgestrel plasma levels during continuous administration, 123
- release rate, 483

## Capsules releasing levonorgestrel, contraception after pregnancy termination, 473

## Cauda epididymides, effect of gossypol (rat), 391

## Cervical dilatation in late first trimester abortion, comparison of different

- prostaglandin analogues and laminaria, 51

## Cervical dilatation in termination of first trimester pregnancy, 16,16-dimethyl-trans-

- $\Delta^2$  PGE<sub>1</sub> methyl ester, 339

## Cervical mucus changes, anovulatory luteal cycle (monkey), 505

## Cervical state at time of vacuum aspiration, pre-operative 16,16-dimethyl-trans-

- $\Delta^2$  PGE<sub>1</sub> methyl ester, 339

## Characterization of a human anti-hCG antiserum, 627

## Cholesterol level,

- effect of injectable medroxyprogesterone acetate, 161
- effect of subdermal implant capsules containing levonorgestrel, 281
- effect of TCu 200, 281

## Chromatographic profile of D-trp<sup>6</sup>-pro<sup>9</sup>-NET-LHRH, assessment for stability of solutions, 195

## Clinical chemistry tests,

- effect of subdermal implant capsules containing levonorgestrel, 281
- effect of TCu 200, 281

## Clinical data,

- first trimester pregnancy termination using polymeric controlled release vaginal delivery system containing (15S)15-methyl PGF<sub>2 $\alpha$</sub>  methyl ester, 141

## CONTRACEPTION

- second trimester pregnancy termination using polymeric controlled release
  - vaginal delivery system containing (15S)15-methyl PGF<sub>2α</sub> methyl ester, 141
- Clinical factors influencing pill efficacy, 531
- Clinical observations, zoapatle, 211
- Clinical studies, zoapatle aqueous crude extract (rat, dog), 255
- Clotting activity,
  - interaction between ethanol and ethinyl estradiol (rat), 401
  - interaction between ethanol and norethindrone (rat), 401
- Comparative evaluation of copper 7, Multiload copper 250 and T copper-220C IUDs, 75
- Complications after discharge from hospital, pre-operative 16,16-dimethyl-trans- $\Delta^2$ PGE<sub>1</sub> methyl ester, 339
- Compounds isolated from zoapatle, 211
- Continuation,
  - levonorgestrel-releasing capsules, 473
  - Nova-T, 473
- Continuation/withdrawal, comparison of ethinyl oestradiol + levonorgestrel monophasic and triphasic versions, 439
- Continuation rate,
  - comparison of mestranol + norethindrone and ethinyl estradiol + norethindrone, 453
  - effect of vitamin supplementation during oral contraceptive use, 465
- Contraceptive efficacy, testosterone + estradiol implant (monkey), 383
- Contraceptive methods, prevalence rate of vaginal colonization of *E. coli*, 497
- Contragestative effects, RMI 12,936 (hamster), 95
- Copper corrosion, MLCu250 and MLCu375 IUDs, 85
- Copper T, fertility regulation in nursing women, 13
- Corrosion and time of use, MLCu250 and MLCu375 IUDs, 85
- Corrosion of filamentous intrauterine copper, MLCu250 and MLCu375, 85
- Cortisol binding globulin level,
  - effect of ethinylestradiol + desogestrel monophasic, 577
  - effect of ethinylestradiol + desogestrel sequential, 577
  - effect of ethinylestradiol + levonorgestrel triphasic, 577
- Cortisol level,
  - effect of ethinylestradiol + desogestrel monophasic, 577
  - effect of ethinylestradiol + desogestrel sequential, 577
  - effect of ethinylestradiol + levonorgestrel triphasic, 577
  - effect of subdermal implant capsules containing levonorgestrel, 281
  - effect of TCu 200, 281
- Covered rods containing levonorgestrel,



- levonorgestrel plasma levels during continuous administration, 123
- release rate, 483
- Cu-7,
  - incidence of pelvic inflammatory disease in clinical trials, 111
  - randomised comparative evaluation of Cu-IUDs, 75
- Cycle length,
  - anovulatory luteal cycle (monkey), 505
  - comparison of ethinyl oestradiol + levonorgestrel monophasic and triphasic versions, 439
  - effect of agonistic and antagonistic analogues of LH-RH (monkey), 619
- D-Trp<sup>6</sup>-LH-RH, effect on ovulation (monkey), 619
- D-trp<sup>6</sup>-pro<sup>9</sup>-NET-LHRH, assessment of stability of solutions, 195
- Danazol, side effects when used for postcoital contraception, 39
- Deglycosylated hCG, effect on ovulation (rat), 515
- 9-Deoxo-16,16-dimethyl-9-methylene PGE<sub>2</sub>, preoperative cervical dilatation in late first trimester, 51
- Development of prolactinomas, influence of oral contraceptive steroids, 69
- 20 $\alpha$ -Dihydroprogesterone level, effect of vaginal device releasing progesterone prematurely during proliferative phase, 177
- Dilatation of cervix in late first trimester abortion, comparison of different prostaglandin analogues and laminaria, 51
- Dilatation of cervix in termination of first trimester pregnancy, 16,16-dimethyl-trans- $\Delta^2$  PGE<sub>1</sub> methyl ester, 339
- 16,16-Dimethyl-trans- $\Delta^2$  PGE<sub>1</sub> methyl ester,
  - preoperative cervical dilatation in late first trimester, 51
  - pre-operative cervical dilatation in termination of first trimester pregnancy, 339
- Discontinuation, norethisterone during breast-feeding, 563
- Drug interactions, oral contraceptive regimens, 531
- Duration of breast-feeding, effect of norethisterone, 563
- Duration of use, effect on incidence of pelvic inflammatory disease during Cu-7 clinical trials, 111
- Dysmenorrhea,
  - effect of levonorgestrel-releasing capsules, 473
  - effect of Nova-T, 473
- E. coli* vaginal colonization, significantly associated factors, 497
- Early first trimester pregnancy termination, polymeric controlled release vaginal delivery system containing (15S)15-methyl PGF<sub>2</sub> $\alpha$  methyl ester, 141

## CONTRACEPTION

- Ecological and botanical determinants, zoapatle, 227
- Effectiveness and interfering factors, oral contraceptive regimens, 531
- Efficacy, comparison of ethinyl oestradiol + levonorgestrel monophasic and triphasic versions, 439
- Ejaculate volume, effect of testosterone + estradiol implant (monkey), 363
- Electric pump, use in vacuum aspiration, 63
- Endocrine properties, effect of RMI 12,936 (rat, hamster, rabbit), 95
- Endometrial effect, progesterone released prematurely during proliferative phase, 177
- Endometrial plasminogen activator activity, effect of IUDs, 131
- Endometrium, subcellular distribution of estradiol and estrone during menstrual cycle, 409
- Epididymis, effect of gossypol (rat), 391
- Estradiol + testosterone,
  - contraceptive efficacy (monkey), 383
  - effect on testis function (monkey), 347
  - somatic tissue responses (monkey), 363
- Estradiol and estrone, subcellular distribution in endometrium and myometrium during menstrual cycle, 409
- Estradiol blood production rate, effect of testosterone + estradiol implant (monkey), 347
- Estradiol level,
  - during menstrual cycle, 409
  - during menstrual cycle of lactating women, 299
  - effect of A-LH-RH (monkey), 619
  - effect of D-Trp<sup>6</sup>-LH-RH (monkey), 619
  - effect of ethinylestradiol + desogestrel monophasic, 577
  - effect of ethinylestradiol + desogestrel sequential, 577
  - effect of ethinylestradiol + levonorgestrel triphasic, 577
  - effect of ethinyl estradiol + norgestrel during menstrual cycle of lactating women, 299
  - effect of norethisterone enanthate, 553
  - effect of Nova-T, 553
  - effect of subdermal implant capsules containing levonorgestrel, 281
  - effect of TCU 200, 281
  - effect of testosterone + estradiol implant (monkey), 347
  - effect of vaginal device releasing progesterone prematurely during proliferative phase, 177
  - normal cycle (monkey), 619
  - normal menstruating women, 329

## CONTRACEPTION

- testicular production after testosterone + estradiol implant (monkey), 347
- Estradiol metabolic clearance rate, effect of testosterone + estradiol implant (monkey), 347
- 4-Estrene-3,17-dione, effect on 17 $\beta$ -hydroxysteroid oxidoreductase activity (dog), 431
- Estrogen determination, morning urine samples from normally menstruating women, 329
- Estrone level, during menstrual cycle, 409
- Ethanol and contraceptive steroids, interaction on clotting activity (rat), 401
- Ethinylestradiol + desogestrel monophasic, effect on plasma hormone levels, 577
- Ethinylestradiol + desogestrel sequential, effect on plasma hormone levels, 577
- Ethinyl estradiol + l-norgestrel, effect on biliary lipid composition in Mexican women, 591
- Ethinyl estradiol + levonorgestrel, fertility regulation in nursing women, 1, 13, 27
- Ethinylestradiol + levonorgestrel triphasic, effect on plasma hormone levels, 577
- Ethinyl estradiol + norethindrone,
  - comparison with mestranol + norethindrone in clinical trials, 453
  - effect of daily vitamin supplementation on side effects and discontinuation, 465
- Ethinyl estradiol + norgestrel,
  - effect on gonadotropin responses to LH-RH in lactating women with regular menstrual cycles resumed, 605
  - effects on pituitary-ovarian function during menstrual cycle of lactating women, 299
- Ethinyl estradiol and ethanol, interaction on clotting activity (rat), 401
- Ethinyl oestradiol + levonorgestrel, comparison of monophasic and triphasic versions on acceptability, 439
- Ethinylloestradiol + norgestrel, side effects when used for postcoital contraception, 39
- Ethinylestradiol + levonorgestrel, effect on levels of hemoglobin, serum iron and iron binding capacity in anemic women, 311
- Ethinylestradiol + levonorgestrel with ferrous fumarate, effect on levels of hemoglobin, serum iron and iron binding capacity in anemic women, 311
- Ethinylloestradiol + norethisterone, pharmacokinetics after morning or evening administration, 153
- Ethinylloestradiol level, after administration of ethinylloestradiol + norethisterone, 153
- Expulsion, randomised comparative evaluation of Cu-IUDs, 75
- Factors significantly associated with vaginal carriage of *E. coli*, 497
- Ferritin level,
  - effect of T Cu 220, 289
  - predictive value in anemia development after T Cu 220 insertion, 289
- Fertility,
  - effect of cadmium (rat), 521

## CONTRACEPTION

- effect of cadmium + zinc (rat), 521
- effect of testosterone + estradiol implant (monkey), 383
- Fertility regulation in nursing women,
  - copper T, 13
  - ethinyl estradiol + levonorgestrel, 1, 13, 27
- Filamentous intrauterine copper corrosion, MLCu250 and MLCu375, 85
- First treatment cycle, effectiveness of oral contraceptive regimens, 531
- First trimester pregnancy termination, pre-operative cervical dilatation using 16,16-dimethyl-trans- $\Delta^2$  PGE<sub>1</sub> methyl ester, 339
- FSH (follicle stimulating hormone)
  - FSH level,
    - during menstrual cycle of lactating women, 299
    - effect of ethinylestradiol + desogestrel monophasic, 577
    - effect of ethinylestradiol + desogestrel sequential, 577
    - effect of ethinylestradiol + levonorgestrel triphasic, 577
    - effect of ethinyl estradiol + norgestrel during menstrual cycle of lactating women, 299
    - effect of ethinylestradiol + norgestrel to response to LH-RH, 605
    - effect of ethinyl estradiol + norgestrel to response to LH-RH in lactating women with regular menstrual cycles resumed, 605
    - effect of norethisterone enanthate, 553
    - effect of Nova-T, 553
    - effect of testosterone + estradiol implant (monkey), 347
    - response to LH-RH, 605
    - response to LH-RH in lactating women with regular menstrual cycles resumed, 605
- Glucose level,
  - effect of subdermal implant capsules containing levonorgestrel, 281
  - effect of TCu 200, 281
- Gonadotropin responses to LH-RH in lactating women with regular menstrual cycles resumed, effect of ethinyl estradiol + norgestrel, 605
- Gossypol,
  - clinical study of vaginal contraceptive efficacy, 571
  - effect on epididymis (rat), 391
- Growth of prolactinomas, influence of oral contraceptive steroids, 69
- Hand pump, use in vacuum aspiration, 63
- hCG (human chorionic gonadotropin)
- hCG antagonist, effect on ovulation (rat), 515

## CONTRACEPTION

- hCG vaccine development, a proposed standard for laboratories, 627
- hCH/LH level,
  - effect of norethisterone enanthate, 553
  - effect of Nova-T, 553
- HDL (high density lipoprotein)
- HDL-cholesterol,
  - effect of subdermal implant capsules containing levonorgestrel, 281
  - effect of TCU 200, 281
- Hematological parameters, interaction between ethanol and contraceptive steroids (rat), 401
- Hematological results, effect of zoapatle aqueous crude extract (rat), 255
- Hematology, effect of testosterone + estradiol implant (monkey), 363, 383
- Hemoglobin level,
  - effect of ethynylestradiol + levonorgestrel in anemic women, 311
  - effect of ethynylestradiol + levonorgestrel with ferrous fumarate in anemic women, 311
  - effect of levonorgestrel-releasing capsules, 473
  - effect of Nova-T, 473
  - effect of TCU 220, 289
  - effects of IUDs in anemic women, 311
- Hexanic extract of zoapatle aqueous crude extract, effect on uterine contractility (rat, guinea pig), 267
- Homogeneous rods containing levonorgestrel, release rate, 483
- Hormonal consequences of missed pills, oral contraceptive regimens, 531
- Hormone changes during placebo week, oral contraceptive regimens, 531
- 17  $\beta$ -Hydroxy-7  $\alpha$ -methyl-5-androstene-3-one (RMI 12,936), endocrine properties (rat, hamster, rabbit), 95
- 17-Hydroxyprogesterone level, effect of vaginal device releasing progesterone prematurely during proliferative phase, 177
- 17  $\beta$ -Hydroxysteroid oxidoreductase activity,
  - effect of different steroids on testosterone synthesis (dog), 431
  - molecular characteristics necessary for competitive inhibition, 431
- Inadvertent administration during very early pregnancy, oral contraceptive regimens, 531
- Inadvertent pregnancies, oral contraceptive users, 531
- Indomethacin, use in study of morphology and functions of anovulatory luteinized follicles (monkey), 505
- Infant growth,

## CONTRACEPTION

- effect of copper T in nursing women, 13
- effect of ethinyl estradiol + levonorgestrel in nursing women, 1, 13, 27
- Inhibition of testosterone synthesis in testis (dog), 431
- Injectable contraceptive,
  - medroxyprogesterone acetate, 161
  - norethisterone enanthate, 553, 591
- Inorganic phosphorus level,
  - effect of subdermal implant capsules containing levonorgestrel, 281
  - effect of TCu 200, 281
- Interfering factors and effectiveness, oral contraceptive regimens, 531
- Intermenstrual bleeding, comparison of ethinyl oestradiol + levonorgestrel monophasic and triphasic versions, 439
- Intracellular distribution,
  - estradiol and estrone in endometrium during menstrual cycle, 409
  - estradiol and estrone in myometrium during menstrual cycle, 409
- Intrauterine device (IUD),
  - copper T, 13
  - Cu7, 75, 111
  - effect on plasminogen activator activity in uterine tissue, 131
  - Lipples loop, 311
  - Lippes loop D, 131
  - MLCu250, 85
  - MLCu375, 85
  - Multiload Cu250, 75
  - Nova-T, 473, 553
  - Progestasert, 311
  - Saf-T-Coil, 131
  - TCu 200, 281
  - TCu 220, 289
  - TCu-220C, 75, 311
- Ionic content, different aqueous zoapatle crude extracts, 239
- IPAS Modified Gynecologic Syringe, use in vacuum aspiration, 63
- Iron binding capacity,
  - effect of ethynylestradiol + levonorgestrel in anemic women, 311
  - effect of ethynylestradiol + levonorgestrel with ferrous fumarate in anemic women, 311
  - effects of IUDs in anemic women, 311
- IUD (intrauterine device)

- Kauradienoic acid ((-)-kaura-9(11),16-dien-19-oic acid),
  - effect on uterine contractility (rat, guinea pig), 267
  - obtained from hexanic extract of zoapatle leaves, 267
- Lactating women, effect of ethinyl estradiol + norgestrel on pituitary-ovarian function during menstrual cycle, 299
- Lactating women with regular menstrual cycles resumed, effect of ethinyl estradiol + norgestrel on gonadotropin responses to LH-RH, 605
- Lactation,
  - effect of copper T, 13
  - effect of ethinyl estradiol + levonorgestrel, 1, 13, 27
- Laminaria tent, preoperative cervical dilatation in late first trimester, 51
- Late first trimester abortion, comparison of different prostaglandin analogues and laminaria for preoperative dilatation of cervix, 51
- LDL (low density lipoprotein)
- LDL-cholesterol,
  - effect of subdermal implant capsules containing levonorgestrel, 281
  - effect of TCu 200, 281
- Levonorgestrel level,
  - during use of capsules containing levonorgestrel, 123
  - during use of covered rods containing levonorgestrel, 123
  - influence of period from application of tourniquet to withdrawal of blood, 123
  - sample taken from arm with implants vs. other arm, 123
- Levonorgestrel release rates, capsules, homogeneous rods and covered rods, 483
- Levonorgestrel-containing capsules,
  - effect on clinical chemistry, 281
  - levonorgestrel plasma levels during continuous administration, 123
  - release rate, 483
- Levonorgestrel-containing covered rods,
  - levonorgestrel plasma levels during continuous administration, 123
  - release rate, 483
- Levonorgestrel-containing homogeneous rods, release rate, 483
- Levonorgestrel-releasing capsules, contraception after pregnancy termination, 473
- LH (luteinizing hormone or immunoreactive lutropin)
- LH level,
  - during menstrual cycle of lactating women, 299
  - effect of A-LH-RH (monkey), 619

## CONTRACEPTION

- effect of D-Trp<sup>6</sup>-LH-RH (monkey), 619
- effect of ethinylestradiol + desogestrel monophasic, 577
- effect of ethinylestradiol + desogestrel sequential, 577
- effect of ethinylestradiol + levonorgestrel triphasic, 577
- effect of ethinyl estradiol + norgestrel during menstrual cycle of lactating women, 299
- effect of ethinyl estradiol + norgestrel to response to LH-RH, 605
- effect of ethinyl estradiol + norgestrel to response to LH-RH in lactating women with regular menstrual cycles resumed, 605
- effect of testosterone + estradiol implant (monkey), 347
- effect of vaginal device releasing progesterone prematurely during proliferative phase, 177
- normal cycle (monkey), 619
- normal menstruating women, 329
- response to LH-RH, 605
- response to LH-RH in lactating women with regular menstrual cycles resumed, 605
- LH/hCG level,
  - effect of norethisterone enanthate, 553
  - effect of Nova-T, 553
- LHRH (luteinizing hormone releasing hormone)
- LHRH analogue,
  - D-Trp<sup>6</sup>-LH-RH, 619
  - D-trp<sup>6</sup>-pro<sup>9</sup>-NET-LHRH, 195
  - [N-Ac-D-Trp<sup>1,3</sup>,D-p-Cl-Phe<sup>2</sup>,D-Phe<sup>6</sup>,D-Ala<sup>10</sup>]-LH-RH, 619
- LH-RH stimulation, effect of ethinyl estradiol + norgestrel to gonadotropin responses in lactating women with regular menstrual cycles resumed, 605
- Lipids and side effects, effect of medroxyprogesterone acetate in Nigerian women, 161
- Lipoprotein pattern,
  - effect of subdermal implant capsules containing levonorgestrel, 281
  - effect of TCU 200, 281
- Lippes loop, effect on levels of hemoglobin, serum iron and iron binding capacity in anemic women, 311
- Lippes loop D, effect on plasminogen activator activity in uterine tissue, 131
- Lithosperm (Lithospermum ruderale plant extract)
- Lithospermum ruderale plant extract (lithosperm), effect on thyroidal <sup>32</sup>P uptake (chick), 639



- Luteal phase length,
  - anovulatory luteal cycle (monkey), 505
  - effect of agonistic and antagonist analogues of LH-RH (monkey), 619
- Luteinization of unruptured follicles, anovulatory luteal cycle (monkey), 505
- Luteinized anovulatory follicle (monkey), 505
- Mechanism of action,
  - estrogen-progestogen combinations, 531
  - progestogen-only formulations, 531
- Medroxyprogesterone acetate, effect on blood lipids and side effects in Nigerian women, 161
- Menses induction, polymeric controlled release vaginal delivery system containing (15S)15-methyl  $\text{PGF}_{2\alpha}$  methyl ester, 141
- Menstrual bleeding, effect of norethisterone during breast-feeding, 563
- Menstrual cycle,
  - effect of vaginal device releasing progesterone prematurely during proliferative phase, 177
  - subcellular distribution of estradiol and estrone in endometrium and myometrium, 409
- Menstrual cycle of lactating women, effect of ethinyl estradiol + norgestrel on pituitary-ovarian function, 299
- Menstrual disturbances,
  - levonorgestrel-releasing capsules, 473
  - Nova-T, 473
- Menstrual flow,
  - effect of levonorgestrel-releasing capsules, 473
  - effect of Nova-T, 473
- Mestranol + norethindrone,
  - comparison with ethinyl estradiol + norethindrone in clinical trials, 453
  - effect of daily vitamin supplementation on side effects and discontinuation, 465
- Metabolic clearance rate of estradiol, effect of testosterone + estradiol implant (monkey), 347
- Metabolic clearance rate of testosterone, effect of testosterone + estradiol implant (monkey), 347
- 15-Methyl- $\text{PGF}_{2\alpha}$  methyl ester, preoperative cervical dilatation in late first trimester, 51
- Mexican women, effects of synthetic steroid contraceptives on biliary lipid composition, 591
- Missed oral contraceptive pills,

## CONTRACEPTION

- hormonal consequences, 531
- risk of pregnancy, 531
- Morning or evening administration, pharmacokinetics of ethinyloestradiol + norethisterone, 153
- Morning urine samples from normally menstruating women, determination of total urinary estrogens, 329
- Morphology of luteinized anovulatory follicle (monkey), 505
- Motility initiation of spermatozoa, effect of gossypol on epididymis (rat), 391
- Multiload Cu250, randomized comparative evaluation of Cu-IUDs, 75
- Myometrium, subcellular distribution of estradiol and estrone during menstrual cycle, 409
- [N-Ac-D-Trp<sup>1,3</sup>, D-p-Cl-Phe<sup>2</sup>, D-Phe<sup>6</sup>, D-Ala<sup>10</sup>]-LH-RH (A-LH-RH), effect on ovulation (monkey), 619
- Naproxen-sodium, use in study of morphology and functions of anovulatory luteinized follicles (monkey), 505
- Nausea, danazol compared with ethinyloestradiol + norgestrel when used for postcoital contraception, 39
- Nigerian women, effect of medroxyprogesterone acetate on blood lipids and side effects, 161
- Norethindrone and ethanol, interaction on clotting activity (rat), 401
- Norethisterone, acceptability during breast-feeding, 563
- Norethisterone and phenytoin, interaction (monkey) 423
- Norethisterone enanthate,
  - effect on biliary lipid composition in Mexican women, 591
  - postabortal contraception, 553
- Norethisterone level,
  - after administration of ethinyloestradiol + norethisterone, 153
  - after postabortal norethisterone enanthate, 553
  - effect of phenytoin (monkey), 423
- Nova-T,
  - contraception after pregnancy termination, 473
  - postabortal contraception, 553
- Nulliparous women, incidence of pelvic inflammatory disease during Cu-7 clinical trials, 111
- Nursing women,
  - influence of copper T, 13
  - influence of ethinyl estradiol + levonorgestrel on lactation and infant growth, 1, 13, 27

Onset of post-treatment period, danazol compared with ethinyloestradiol + norgestrel when used for postcoital contraception, 39

Operative complications at vacuum aspiration, pre-operative 16,16-dimethyl-trans- $\Delta^2$  PGE<sub>1</sub> methyl ester, 339

Oral contraceptive,

drug interactions, 531

effectiveness and interfering factors, 531

ethinyloestradiol + desogestrel monophasic, 577

ethinyloestradiol + desogestrel sequential, 577

ethinyl estradiol + 1-norgestrel, 591

ethinyl estradiol + levonorgestrel, 1, 13, 27

ethinyloestradiol + levonorgestrel triphasic, 577

ethinyl estradiol + norethindrone with ferrous fumarate, 453, 465

ethinyl estradiol + norgestrel, 299, 605

ethinyl oestradiol + levonorgestrel, 439

ethinyl oestradiol + levonorgestrel triphasic, 439

ethinyloestradiol + levonorgestrel, 311

ethinyloestradiol + levonorgestrel with ferrous fumarate, 311

ethinyloestradiol + norethisterone, 153

mechanism of action, 531

mestranol + norethindrone with ferrous fumarate, 453, 465

norethisterone, 563

Oral contraceptive steroids, influence on development or growth of prolactinomas, 69

Oral contraceptive users, inadvertent pregnancies, 531

Organ weight assay, RMI 12, 936 (rat), 95

Outcome variables, vacuum aspiration with IPAS Modified Gynecologic Syringe compared with electric pump and standard hand pump, 63

Ovarian cycle, plasminogen activator activity during different phases, 131

Ovarian effect, progesterone released prematurely during proliferative phase, 177

Ovulation,

anovulatory luteal cycle (monkey), 505

effect of agonistic and antagonistic analogues of LH-RH (monkey), 619

effect of hCG antagonist (rat), 515

Oxytocin, uterine response (guinea pig), 239

Parous women, incidence of pelvic inflammatory disease during Cu-7 clinical trials, 111

Pelvic inflammatory disease, incidence in clinical trials with Cu-7, 111

PG (prostaglandin)

Pharmacokinetic parameters for ethinyloestradiol, after morning or evening administration

## CONTRACEPTION

- of ethinyloestradiol + norethisterone, 153
- Pharmacokinetic parameters for norethisterone, after morning or evening administration of ethinyloestradiol + norethisterone, 153
- Pharmacokinetics after morning or evening administration, ethinyloestradiol + norethisterone, 153
- 16-Phenoxy- $\omega$ -17,18,19,20-tetranor PGE<sub>2</sub> methyl sulfonylamide, preoperative cervical dilatation in late first trimester, 51
- Phenytoin and norethisterone, interaction (monkey), 423
- Phospholipids level, effect of injectable medroxyprogesterone acetate, 161
- Pill dosage and unusual pill regimens, effectiveness of oral contraceptive regimens, 531
- Pituitary, ovarian and endometrial effects, progesterone released prematurely during proliferative phase, 177
- Pituitary-ovarian function during menstrual cycle of lactating women, effect of ethinyl estradiol + norgestrel, 299
- Plasma renin activity,
  - effect of ethinylestradiol + desogestrel monophasic, 577
  - effect of ethinylestradiol + desogestrel sequential, 577
  - effect of ethinylestradiol + levonorgestrel triphasic, 577
- Plasminogen activator, changes in uterine tissue induced by IUDs, 131
- Platelet count, interaction between ethanol and contraceptive steroids (rat), 401
- Postabortal contraception,
  - norethisterone enanthate, 553
  - Nova-T, 553
- Postcoital contraceptive,
  - danazol, 39
  - ethinyloestradiol + norgestrel, 39
- Postcoital test, effect of gossypol, 571
- Potassium concentration, effect of gossypol on epididymis (rat), 391
- Predictive value of serum ferritin in anemia development after T Cu 220 insertion, 289
- Pregnancy,
  - effect of synthetic androstane derivatives (baboon), 201
  - inadvertent administration of oral contraceptives, 531
- Pregnancy termination,
  - immediate contraception with levonorgestrel-releasing capsules, 473
  - immediate contraception with Nova-T, 473

## CONTRACEPTION

- Preoperative cervical dilatation in late first trimester, comparison of different prostaglandin analogues and laminaria, 51
- Pre-operative cervical dilatation in termination of first trimester pregnancy, 16,16-dimethyl-trans- $\Delta^2$  PGE<sub>1</sub> methyl ester, 339
- Progestasert, effect on levels of hemoglobin, serum iron and iron binding capacity in anemic women, 311
- Progestational/antiprogesterational activity, effect on RMI 12,936 (rat, rabbit), 95
- Progesterone level,
- anovulatory luteal cycle (monkey), 505
  - during menstrual cycle of lactating women, 299
  - effect of A-LH-RH (monkey), 619
  - effect of D-Trp<sup>6</sup>-LH-RH (monkey), 619
  - effect of ethinylestradiol + desogestrel monophasic, 577
  - effect of ethinylestradiol + desogestrel sequential, 577
  - effect of ethinylestradiol + levonorgestrel triphasic, 577
  - effect of ethinyl estradiol + norgestrel during menstrual cycle of lactating women, 299
  - effect of norethisterone enanthate, 553
  - effect of Nova-T, 553
  - effect of synthetic androstane derivatives (baboon), 201
  - effect of vaginal device releasing progesterone prematurely during proliferative phase, 177
  - normal cycle (monkey), 619
- Progesterone released prematurely during proliferative phase, pituitary, ovarian and endometrial effects, 177
- Prolactin level,
- during menstrual cycle, 299, 605
  - during menstrual cycle of lactating women, 299, 605
  - effect of ethinylestradiol + desogestrel monophasic, 577
  - effect of ethinylestradiol + desogestrel sequential, 577
  - effect of ethinylestradiol + levonorgestrel triphasic, 577
  - effect of ethinyl estradiol + norgestrel, 605
  - effect of ethinyl estradiol + norgestrel during menstrual cycle of lactating women, 299
  - effect of ethinyl estradiol + norgestrel in lactating women with regular menstrual cycles resumed, 605

## CONTRACEPTION

- Prolactinomas, influence of oral contraceptive steroids on development or growth, 69
- Proliferative phase premature exposure to progesterone, pituitary, ovarian and endometrial effects, 177
- Proposed standard for laboratories involved in development of hCG vaccines, 627
- Prostaglandin analogue,
  - 9-deoxo-16,16-dimethyl-9-methylene  $\text{PGE}_2$ , 51
  - 16,16-dimethyl-trans- $\Delta^2\text{PGE}_1$  methyl ester, 51, 339
  - 15-methyl  $\text{PGE}_2$   $\alpha$  methyl ester, 51
  - 16-phenoxy- $\omega$ -17,18,19,20-tetranor  $\text{PGE}_2$  methyl sulfonylamide, 51
  - (15S)15-methyl  $\text{PGF}_{2\alpha}$  methyl ester, 141
- Prostaglandin analogues, comparison for preoperative dilatation of cervix in late first trimester abortion, 51
- Protein pattern of cauda fluid, effect of gossypol on epididymis (rat), 391
- Quatelet's index,
  - effect of ethinyl estradiol + 1-norgestrel, 591
  - effect of norethisterone enanthate, 591
- Release rates of levonorgestrel, capsules, homogeneous rods and covered rods, 483
- Removals,
  - levonorgestrel-releasing capsules, 473
  - Nova-T, 473
  - randomised comparative evaluation of Cu-IUDs, 75
- Reproductive organ weights,
  - effect of cadmium (rat), 521
  - effect of cadmium + zinc (rat), 521
- Reproductive tissues, effect of testosterone + estradiol implant (monkey), 363
- Risk of pregnancy, missed oral contraceptive pills, 531
- RMI 12,936 (17 $\beta$ -hydroxy-7 $\alpha$ -methyl-5-androstene-3-one)
- (15S)15-methyl  $\text{PGF}_{2\alpha}$  free acid and methyl ester, extraction from plasma, purification and quantitation, 141
- (15S)15-methyl  $\text{PGF}_{2\alpha}$  level in plasma, polymeric controlled release vaginal delivery system, 141
- (15S)15-methyl  $\text{PGF}_{2\alpha}$  methyl ester, polymeric controlled release vaginal delivery system for menses induction and second trimester pregnancy termination, 141
- Saf-T-Coil, effect on plasminogen activator activity in uterine tissue, 131
- Second trimester pregnancy termination, polymeric controlled release vaginal delivery system containing (15S)15-methyl  $\text{PGF}_{2\alpha}$  methyl ester, 141

## CONTRACEPTION

- Semen characteristics, effect of testosterone + estradiol implant (monkey), 383
- Serum iron level,  
    effect of ethinylestradiol + levonorgestrel in anemic women, 311  
    effect of ethinylestradiol + levonorgestrel with ferrous fumarate in  
        anemic women, 311  
    effects of IUDs in anemic women, 311
- Sex hormone binding globulin,  
    effect of ethinylestradiol + desogestrel monophasic, 577  
    effect of ethinylestradiol + desogestrel sequential, 577  
    effect of ethinylestradiol + levonorgestrel triphasic, 577
- Side effects,  
    comparison of different prostaglandin analogues and laminaria for preoperative  
        cervical dilatation in late first trimester abortion, 51  
    comparison of ethinyl oestradiol + levonorgestrel monophasic and triphasic versions,  
        439  
    comparison of mestranol + norethindrone and ethinyl estradiol + norethindrone, 453  
    danazol compared with ethinylestradiol + norgestrel when used for postcoital  
        contraception, 39  
    effect of vitamin supplementation during oral contraceptive use, 465  
    injectable medroxyprogesterone acetate, 161  
    levonorgestrel-releasing capsules, 473  
    Nova-T, 473  
    pre-operative 16,16-dimethyl-trans- $\Delta^2$  PGE<sub>1</sub> methyl ester, 339
- Sodium concentration, effect of gossypol on epididymis (rat), 391
- Somatic tissue responses, effect of testosterone + estradiol implant (monkey), 363
- Sperm concentration, effect of gossypol on epididymis (rat), 391
- Sperm motility  
    effect of gossypol, 571  
    effect of gossypol on epididymis (rat), 391
- Sperm population,  
    effect of cadmium (rat), 521  
    effect of cadmium + zinc (rat), 521
- Sperm production, effect of testosterone + estradiol implant (monkey), 347
- Spinnbarkeit, normal menstruating women, 329
- Stability of solutions, assessment for D-trp<sup>6</sup>-pro<sup>9</sup>-NET-LHRH, 195
- Steroids, effect on testosterone synthesis in testis (dog), 431

## CONTRACEPTION

- Subcellular distribution, estradiol and estrone in endometrium and myometrium during menstrual cycle, 409
- Subdermal implant,
- capsules containing levonorgestrel, 123, 281
  - capsules releasing levonorgestrel, 483
  - covered rods containing levonorgestrel, 123
  - covered rods releasing levonorgestrel, 483
  - homogeneous rods releasing levonorgestrel, 483
  - levonorgestrel-releasing capsules, 473
- Subdermal polydimethylsiloxane implant, testosterone + estradiol (monkey), 347, 363, 383
- TCu 200, effect on clinical chemistry, 281
- T Cu 220,
- effect of serum ferritin and other hematological parameters, 289
  - predictive value of serum ferritin in anemia development after insertion, 289
- TCu-220C,
- effect on levels of hemoglobin, serum iron and iron binding capacity in anemic women, 311
  - randomized comparative evaluation on Cu-IUDs, 75
- Termination rates, randomised comparative evaluation of Cu-IUDs, 75
- Terminations,
- comparison of mestranol + norethindrone and ethinyl estradiol + norethindrone, 453
  - effect of vitamin supplementation during oral contraceptive use, 465
- Testis, inhibition of testosterone synthesis by steroids (dog), 431
- Testis function, effect of testosterone + estradiol implant (monkey), 347
- Testosterone + estradiol,
- contraceptive efficacy (monkey), 383
  - effect on testis function (monkey), 347
  - somatic tissue responses (monkey), 363
- Testosterone blood production rate, effect of testosterone + estradiol implant (monkey), 347
- Testosterone level,
- effect of cadmium (rat), 521
  - effect of cadmium + zinc (rat), 521
  - effect of ethinylestradiol + desogestrel monophasic, 577
  - effect of ethinylestradiol + desogestrel sequential, 577
  - effect of ethinylestradiol + levonorgestrel triphasic, 577



- effect of subdermal implant capsules containing levonorgestrel, 281
- effect of TCu 200, 281
- effect of testosterone + estradiol implant (monkey), 347
- testicular production after testosterone + estradiol implant (monkey), 347
- Testosterone metabolic clearance rate, effect of testosterone + estradiol implant (monkey), 347
- Testosterone synthesis inhibition in testis (dog), 431
- Thyroid stimulating hormone level,
  - effect of subdermal implant capsules containing levonorgestrel, 281
  - effect of TCu 200, 281
- Thyroid weight,
  - effect of lithosperm (chick), 639
  - effect of lithosperm and propylthiouracil (chick), 639
- Thyroidal <sup>32</sup>P uptake,
  - effect of lithosperm (chick), 639
  - effect of lithosperm and propylthiouracil (chick), 639
  - effect of lithosperm and thyroid-stimulating hormone (chick), 639
- Thyroxine level,
  - effect of subdermal implant capsules containing levonorgestrel, 281
  - effect of TCu 200, 281
- Time of use and corrosion, MLCu250 and MLCu375 IUDs, 85
- Total urinary estrogens, determination in morning urine samples from normally menstruating women, 329
- Toxicological studies, zoapatle aqueous crude extract (rat, dog), 255
- Traditional remedy from Mexico, zoapatle, 211
- Triglycerides level,
  - effect of injectable medroxyprogesterone acetate, 161
  - effect of subdermal implant capsules containing levonorgestrel, 281
  - effect of TCu 200, 281
- Triiodothyronine level,
  - effect of subdermal implant capsules containing levonorgestrel, 281
  - effect of TCu 200, 281
- Triphasic ethinyl oestradiol + levonorgestrel, comparison to monophasic version on acceptability, 439
- Urine samples collected in the morning from normally menstruating women, determination of total urinary estrogens, 329

## CONTRACEPTION

- Use-effectiveness, comparison of mestranol + norethindrone and ethinyl estradiol + norethindrone, 453
- Uterine contractility,  
    effect of hexanic extract of zoapatle aqueous crude extract (rat, guinea pig), 267  
    effect of kauradienoic acid (rat, guinea pig), 267  
    effect of zoapatle aqueous crude extract (rat, guinea pig, dog), 267
- Uterine contractions, increase associated with aqueous plant extract of zoapatle, 211
- Uterine response,  
    dialysed extract of zoapatle crude extract (guinea pig), 239  
    oxytocin (guinea pig), 239
- Uterine tissue, changes of plasminogen activator activity induced by IUDs, 131
- Uterotonic potency, various Montanoa species, 227
- Uterotonic potency of several specimens of zoapatle (guinea pig), 239
- Uterotonic potency of wild and cultivated specimens of zoapatle (guinea pig), 239
- Uterotonic properties, zoapatle aqueous crude extract (guinea pig), 239
- Uterotrophic/estrogenic activity, effect of RMI 12,936 (rat), 95
- Vacuum aspiration, IPAS Modified Gynecologic Syringe compared with electric pump and standard hand pump, 63
- Vaginal administration of abortifacient, polymeric controlled release delivery system containing (15S)15-methyl PGF<sub>2α</sub> methyl ester, 141
- Vaginal colonization of E. Coli,  
    relation to contraceptive methods, 497  
    significantly associated factors, 497
- Vaginal contraceptive, gossypol acetic acid gel, 571
- Vaginal device, releasing progesterone, 177
- Vitamin supplementation, effect on oral contraceptive side effects and discontinuation, 465
- Vomiting, danazol compared with ethinylloestradiol + norgestrel when used for postcoital contraception, 39
- Withdrawal bleeding, comparison of ethinyl oestradiol + levonorgestrel monophasic and triphasic versions, 439
- Zinc, effect on cadmium-induced sterility (rat), 521
- Zoapatle (Montanoa tomentosa (Cerv.) s.s.p. tomentosa (Funk.)),  
    a traditional remedy from Mexico, 211  
    aqueous plant extract associated with increase in uterine contractions, 211  
    biological and uterotonic properties of aqueous plant extract (guinea pig), 239  
    biological observations, 211

## CONTRACEPTION

botanical and ecological determinants, 227

clinical observations, 211

effect of hexanic extract (kauradienoic acid) upon uterine contractility (rat, guinea pig, dog), 267

history, 211

isolation of active principle(s), 211

toxicological and clinical studies of aqueous crude extract (rat, dog), 255

Zoapatle aqueous crude extract,

effect on uterine contractility (rat, guinea pig, dog), 267

effect on uterine strips of different animal species, 239



